CJC-1295 (Modified GRF 1-29) for Growth Hormone Release — Performance & Recovery
GHRH analog with Drug Affinity Complex (DAC) for sustained growth hormone release with extended half-life of 6-8 days.
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, also known as Modified GRF 1-29) with amino acid substitutions at positions 2, 8, 15, and 27 to improve metabolic stability. The DAC (Drug Affinity Complex) version binds to albumin after injection, extending the half-life from ~30 minutes (native GHRH) to 6-8 days. Teichman et al. (J Clin Endocrinol Metab, 2006, PMID: 16352683) published the first human pharmacokinetic study demonstrating dose-dependent sustained GH and IGF-1 elevation for up to 6 days after a single injection. The non-DAC version (Mod GRF 1-29) has a shorter half-life (~30 min) and is often preferred for more physiologic pulsatile GH release. CJC-1295 stimulates GH release through the GHRH receptor on pituitary somatotrophs, preserving the natural GH pulse pattern. Frequently combined with ipamorelin for synergistic GHRH + GH secretagogue effects. NOT FDA-approved.
Indications
- Growth hormone optimization for anti-aging and recovery
- Sustained GH release for body composition improvement
- Enhanced muscle recovery, sleep quality, and tissue repair
- Complementary therapy with GH secretagogues (ipamorelin, GHRP-2)
Mechanism of Action
Natural GHRH production and pituitary responsiveness decline with age, reducing GH pulse amplitude
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| CJC-1295 (DAC) | 100-300 mcg | 2-3 times per week | Long half-life (6-8 days); less frequent dosing needed; steady GH elevation |
| CJC-1295 (no DAC) | 100-300 mcg | 1-3 times daily (before bed preferred) | Short half-life (~30 min); produces pulsatile GH release; more physiologic |
| CJC-1295 (no DAC) + Ipamorelin | 100 mcg + 100-200 mcg | Once daily (before bed) | Synergistic GHRH + secretagogue combination; most popular clinical protocol |
Evidence Grade
GRADE C
Safety & Contraindications
- Not FDA-approved; investigational use only
- DAC version produces sustained GH elevation (may be less physiologic than pulsatile release)
- Injection site reactions: redness, swelling, pain (common with DAC version)
- Monitor IGF-1 to avoid chronically elevated growth hormone axis
- Contraindicated in active malignancy
- Water retention and joint stiffness possible (signs of excessive GH)